IRWD — Ironwood Pharmaceuticals Cashflow Statement
0.000.00%
- $795.50m
- $1.31bn
- $442.74m
Annual cashflow statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 21.5 | 106 | 528 | 175 | -1,032 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 83.6 | 60 | 47.5 | 28.7 | 1,129 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -100 | -0.941 | 17.7 | 2.82 | 11.3 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 10.7 | 169 | 262 | 274 | 183 |
Capital Expenditures | -7.19 | -1.84 | -0.265 | -0.136 | -1,026 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -3.96 | — | 0 | — | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -11.1 | -1.84 | -0.265 | -0.136 | -1,026 |
Financing Cash Flow Items | -9.05 | — | 0 | — | -29.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1.19 | 18.5 | -4.55 | -238 | 277 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.6 | 186 | 257 | 36.1 | -566 |